Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | Ca.HO4P |
| Molecular Weight | 136.057 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Ca++].OP([O-])([O-])=O
InChI
InChIKey=FUFJGUQYACFECW-UHFFFAOYSA-L
InChI=1S/Ca.H3O4P/c;1-5(2,3)4/h;(H3,1,2,3,4)/q+2;/p-2
| Molecular Formula | Ca |
| Molecular Weight | 40.078 |
| Charge | 2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | HO4P |
| Molecular Weight | 95.9793 |
| Charge | -2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.htmlhttp://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttp://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479Curator's Comment: description was created based on several sources, including
https://www.alfa.com/en/catalog/043674/
Sources: https://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.htmlhttp://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttp://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479
Curator's Comment: description was created based on several sources, including
https://www.alfa.com/en/catalog/043674/
Calcium lactate is the salt that consists of two lactate anions for each calcium cation (Ca2+); this salt is used as a calcium supplement to treat hypocalcemia. However, as a source of free calcium, this salt is less convenient than calcium citrate. Calcium lactate inhalation powder also called as PUR118 participated in phase I clinical trials to determine whether this formulation was safe and tolerable in a population of subjects with Cystic Fibrosis (CF). PUR118 also was used in another clinical trials to evaluate its effect on ozone-induced airway Inflammation in healthy normal volunteers in case of Chronic Obstructive Pulmonary Disease (COPD). The obtained results revealed that PUR118 reduced the severity of acute exacerbations in COPD and CF and had the beneficial impacts on mortality, morbidity, and quality of life in affected individuals. However, both studies were discontinued.
Originator
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseHypocalcemia, chronic (treatment) — Oral calcium supplements provide a source of calcium ion for treating calcium depletion occurring in conditions such as chronic hypoparathyroidism, pseudohypoparathyroidism, osteomalacia, rickets, chronic renal failure, and hypocalcemia secondary to the administration of anticonvulsant medications. When chronic hypocalcemia is due to vitamin D deficiency, oral calcium salts may be administered concomitantly with vitamin D analogs. However, calcium phosphate should not be used in patients with hypoparathyroidism or renal failure, since phosphate levels may be too high and giving more phosphate would exacerbate the condition. Calcium supplements should not be used in hyperparathyroidism, unless the need for a calcium supplement is high and the patient is carefully monitored. For treatment of hypocalcemia, supplementation is preferred |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Transient kinetic analysis of the 130-kDa myosin I (MYR-1 gene product) from rat liver. A myosin I designed for maintenance of tension? | 1999 Jul 30 |
|
| Characterization of the human cysteinyl leukotriene CysLT1 receptor. | 1999 Jun 24 |
|
| Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. | 1999 Sep |
|
| Discovery of CP-199,330 and CP-199,331: two potent and orally efficacious cysteinyl LT1 receptor antagonists devoid of liver toxicity. | 1999 Sep 20 |
|
| Cytosolic [Ca(2+)] modulates basal GLUT1 activity and plays a permissive role in its activation by metabolic stress and insulin in rat epithelial cells. | 2000 Aug |
|
| Neuropeptide Y (NPY) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y5 receptors. | 2000 Feb 15 |
|
| alpha(1E) subunits form the pore of three cerebellar R-type calcium channels with different pharmacological and permeation properties. | 2000 Jan 1 |
|
| Vanadate induces calcium signaling, Ca2+ release-activated Ca2+ channel activation, and gene expression in T lymphocytes and RBL-2H3 mast cells via thiol oxidation. | 2000 Jan 15 |
|
| Polyoxygenated dysidea sterols that inhibit the binding of [I125] IL-8 to the human recombinant IL-8 receptor type A. | 2000 May |
|
| Effects of a calcimimetic compound and naturally activating mutations on the human Ca2+ receptor and on Ca2+ receptor/metabotropic glutamate chimeric receptors. | 2000 Nov |
|
| Calmodulin kinases II and IV and calcineurin are involved in leukemia inhibitory factor-induced cardiac hypertrophy in rats. | 2000 Nov 10 |
|
| Mechanism of extracellular calcium regulation of intestinal epithelial tight junction permeability: role of cytoskeletal involvement. | 2000 Oct 15 |
|
| Chemokines induce eosinophil degranulation through CCR-3. | 2000 Sep |
|
| Pilocarpine-induced status epilepticus causes N-methyl-D-aspartate receptor-dependent inhibition of microsomal Mg(2+)/Ca(2+) ATPase-mediated Ca(2+) uptake. | 2000 Sep |
|
| Ca2+-induced contraction of cat esophageal circular smooth muscle cells. | 2001 Apr |
|
| Endothelin-induced changes of secondary messengers in cultured corneal endothelial cells. | 2001 Aug |
|
| Potent inhibition of NFAT activation and T cell cytokine production by novel low molecular weight pyrazole compounds. | 2001 Dec 21 |
|
| Molecular and functional characterization of a family of rat brain T-type calcium channels. | 2001 Feb 9 |
|
| Extracellular calcium-sensing receptor is expressed in rat hepatocytes. coupling to intracellular calcium mobilization and stimulation of bile flow. | 2001 Feb 9 |
|
| Aluminum toxicity alters the regulation of calbindin-D28k protein and mRNA expression in chick intestine. | 2001 Jul |
|
| Analysis of the native quaternary structure of vanilloid receptor 1. | 2001 Jul 27 |
|
| Endothelin- and sarafotoxin-induced receptor-mediated calcium mobilization in a clonal murine osteoblast-like cell line, MC3T3-E1/B. | 2001 Jun |
|
| Vasopressin-stimulated Ca2+ spiking in vascular smooth muscle cells involves phospholipase D. | 2001 Jun |
|
| Long-term alteration of calcium homeostatic mechanisms in the pilocarpine model of temporal lobe epilepsy. | 2001 Jun 8 |
|
| Tight control of exogenous SERCA expression is required to obtain acceleration of calcium transients with minimal cytotoxic effects in cardiac myocytes. | 2001 Mar 2 |
|
| Hypoxia-induced regulation of MAPK phosphatase-1 as identified by subtractive suppression hybridization and cDNA microarray analysis. | 2001 Nov 30 |
|
| Familial intrahepatic cholestasis 1: studies of localization and function. | 2001 Oct |
|
| Microarray analysis of differential gene expression in lead-exposed astrocytes. | 2001 Oct 1 |
|
| Phosphoinositide 3-kinase isoforms selectively couple receptors to vascular L-type Ca(2+) channels. | 2001 Oct 12 |
|
| Replacement of the muscle-specific sarcoplasmic reticulum Ca(2+)-ATPase isoform SERCA2a by the nonmuscle SERCA2b homologue causes mild concentric hypertrophy and impairs contraction-relaxation of the heart. | 2001 Oct 26 |
|
| Regional differences in functional receptor distribution and calcium mobilization in the intact human lens. | 2001 Sep |
|
| Heterologous expression of the Na(+),K(+)-ATPase gamma subunit in Xenopus oocytes induces an endogenous, voltage-gated large diameter pore. | 2001 Sep 1 |
|
| Ameliorative effect of vasopressin-(4-9) through vasopressin V(1A) receptor on scopolamine-induced impairments of rat spatial memory in the eight-arm radial maze. | 2001 Sep 7 |
|
| The role of endogenous human Trp4 in regulating carbachol-induced calcium oscillations in HEK-293 cells. | 2002 Apr 19 |
|
| Interaction of intravenous anesthetics with recombinant human M1-M3 muscarinic receptors expressed in chinese hamster ovary cells. | 2002 Dec |
|
| CXCR4 expression on monocytes is up-regulated by dexamethasone and is modulated by autologous CD3+ T cells. | 2002 Feb |
|
| Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice. | 2002 Jan 15 |
|
| Expression of functional CCR and CXCR chemokine receptors in podocytes. | 2002 Jun 15 |
|
| Investigation of a functional requirement for isoprenylation by the human prostacyclin receptor. | 2002 Mar |
|
| Hypertension-related intermyocyte junction remodelling is associated with a higher incidence of low-K(+)-induced lethal arrhythmias in isolated rat heart. | 2002 Mar |
|
| Alpha(1H) mRNA in single skeletal muscle fibres accounts for T-type calcium current transient expression during fetal development in mice. | 2002 Mar 15 |
|
| Diacylglycerol activates the influx of extracellular cations in T-lymphocytes independently of intracellular calcium-store depletion and possibly involving endogenous TRP6 gene products. | 2002 May 15 |
|
| Molecular cloning and characterization of the human voltage-gated calcium channel alpha(2)delta-4 subunit. | 2002 Sep |
|
| Effects of endothelin B receptor agonists on amyloid beta protein (25-35)-induced neuronal cell death. | 2002 Sep 6 |
|
| A critical interplay between Ca2+ inhibition and activation by Mg2+ of AC5 revealed by mutants and chimeric constructs. | 2002 Sep 6 |
|
| [Prevention of osteoporosis by foods and dietary supplements. Bioavailability of milk micellar calcium phosphate]. | 2006 Oct |
|
| Dietary calcium source influences body composition, glucose metabolism and hormone levels in a mouse model of postmenopausal obesity. | 2009 Jul-Aug |
|
| Effect of calcium phosphate and vitamin D₃ supplementation on bone remodelling and metabolism of calcium, phosphorus, magnesium and iron. | 2014 Jan 17 |
|
| Long-term remineralizing effect of casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) on early caries lesions in vivo: a systematic review. | 2014 Jul |
|
| Dietary interventions for mineral and bone disorder in people with chronic kidney disease. | 2015 Sep 16 |
Sample Use Guides
Proper administration of calcium carbonate or phosphate: Taking tablets 1 to 11/2 hours after meals, unless otherwise directed by physician. Recommended doses for adolescents and adults is 800-1200 mg/day; for pregnat orbreast-feeding females 1200 mg/day.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:59:40 GMT 2025
by
admin
on
Mon Mar 31 17:59:40 GMT 2025
|
| Record UNII |
L11K75P92J
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CODEX ALIMENTARIUS (GSFA) |
INS-341(II)
Created by
admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
|
||
|
JECFA EVALUATION |
INS-341(II)
Created by
admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
24441
Created by
admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
|
PRIMARY | |||
|
47627
Created by
admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
|
PRIMARY | |||
|
100000087353
Created by
admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
|
PRIMARY | |||
|
L11K75P92J
Created by
admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
|
PRIMARY | |||
|
DICALCIUM PHOSPHATE
Created by
admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
|
PRIMARY | |||
|
ANHYDROUS DIBASIC CALCIUM PHOSPHATE
Created by
admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
|
PRIMARY | Description: A white or almost white powder; odourless. Solubility: Practically insoluble in cold water and ethanol (~750 g/l) TS; soluble in dilute acids. Category: Tablet and capsule diluent. Storage: Calcium hydrogen phosphate should be kept in a well-closed container. Labelling: The designation on the container of Calcium hydrogen phosphate should state whether it is the dihydrate or the anhydrous form. Requirement: Calcium hydrogen phosphate contains not less than 30.9% and not more than the equivalent of 31.7% of calcium, Ca, calculated with reference to the ignited substance. | ||
|
L11K75P92J
Created by
admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
|
PRIMARY | |||
|
DBSALT002430
Created by
admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
|
PRIMARY | |||
|
32596
Created by
admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
|
PRIMARY | |||
|
4496
Created by
admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
|
PRIMARY | |||
|
C77523
Created by
admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
|
PRIMARY | |||
|
m2964
Created by
admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
|
PRIMARY | Merck Index | ||
|
CHEMBL2107567
Created by
admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
|
PRIMARY | |||
|
231-826-1
Created by
admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
|
PRIMARY | |||
|
992
Created by
admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
|
PRIMARY | |||
|
DTXSID20872529
Created by
admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
|
PRIMARY | |||
|
C1505
Created by
admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
|
CONCEPT | Dietary Supplement | ||
|
SUB16368MIG
Created by
admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
|
PRIMARY | |||
|
253163
Created by
admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
|
ALTERNATIVE | |||
|
SUB11772MIG
Created by
admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
|
PRIMARY | |||
|
7757-93-9
Created by
admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SOLVATE->ANHYDROUS | |||
|
SOLVATE->ANHYDROUS |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
||
|
|
ACTIVE MOIETY |
|
